



INTERNATIONAL JOURNAL OF TRENDS IN EMERGING RESEARCH AND DEVELOPMENT

INTERNATIONAL JOURNAL OF TRENDS IN EMERGING RESEARCH AND DEVELOPMENT

Volume 4; Issue 3; 2026; Page No. 243-247

Received: 08-02-2026

Accepted: 18-04-2026

Published: 25-05-2026

A Quality by Design-Based Approach for the Development and Optimization of Controlled-Release Oral Dosage Forms

¹Shipate Swapnil Mohan and ²Dr. Umesh Kumar

¹Research Scholar, Department of Pharmacy, Monad University, Hapur, Uttar Pradesh, India

²Professor, Department of Pharmacy, Monad University, Hapur, Uttar Pradesh, India

DOI: <https://doi.org/10.5281/zenodo.23069085>

Corresponding Author: Shipate Swapnil Mohan

Abstract

The goal of controlled-release oral dosage forms is to regulate the rate of drug release for a prolonged amount of time. This leads to fewer doses, less variation in plasma drug concentration, better patient compliance, and long-term therapeutic efficacy. However, because drug-release behaviour depends on numerous interdependent formulation and process variables, developing such dosage forms is difficult. Conventional trial-and-error techniques might need a lot of testing and might not be sufficient to find interactions between significant factors. A methodical, science-based approach to pharmaceutical development, Quality by Design (QbD) entails defining the Quality Target Product Profile (QTPP), identifying Critical Quality Attributes (CQAs), determining Critical Material Attributes (CMAs) and Critical Process Parameters (CPPs), assessing quality risk, applying Design of Experiments (DoE), creating a design space, and creating a suitable control strategy. The present study examines and proposes a methodical strategy based on QbD for the creation and improvement of oral dosage forms with controlled release. To evaluate the impact of formulation and process parameters on drug-release behaviour, published research on matrix tablets, osmotic systems, multilayer tablets, and polymeric controlled-release systems was examined. Polymer concentration, polymer viscosity, drug loading, compression force, coating factors, dissolving behaviour, and release kinetics are all given particular consideration. Research gaps on formulation-process integration, mechanistic comprehension, *in vitro*–*in vivo* correlation, artificial intelligence, continuous manufacturing, and patient-centric formulation design are also identified by the review. QbD-based development can lessen reliance on empirical experimentation while increasing formulation robustness, product understanding, manufacturing uniformity, and lifecycle management.

Keywords: QTPP, CQA, CMA, CPP, Design of Experiments, design space, dissolution, formulation optimisation, controlled-release dosage forms, sustained-release tablets, Quality by Design

1. Introduction

Due to its ease of use, patient acceptance, ease of manufacturing, and comparatively low cost, oral medication delivery is one of the most widely used drug administration methods. Conventional immediate-release formulations, on the other hand, may result in quick drug absorption followed by declining plasma concentrations. Variations between sub-and supratherapeutic medication concentrations may result from repeated administration.

Controlled release oral dose forms have been created to alter the rate and duration of medication release in order to get

around these restrictions. These systems can reduce the overall number of doses, enhance patient compliance with therapy, maintain drug concentrations within a desired therapeutic range for extended periods of time, and possibly lessen side effects linked to high peak concentrations.

Hydrophilic matrix tablets, hydrophobic matrices, osmotic systems, reservoir systems, coated tablets, multilayer tablets, multi-particulates, and polymeric delivery systems are examples of controlled release systems. Among these, matrix tablets are especially appealing due to their formulation flexibility, scalability, and ease of manufacturing.

Controlled-release formulation creation is difficult, though. Drug solubility, particle size, polymer type, concentration, viscosity, excipient characteristics, tablet porosity, compression force, coating thickness, manufacturing conditions, dissolution media, and physiological parameters can all affect drug release. The interdependence of these factors may result in nonlinear effects on medication release.

These interactions might be overlooked by traditional formulation development that takes one factor at a time. A methodical substitute is provided by Quality by Design. Pharmaceutical development is described in ICH Q8 using a risk and science-based methodology. ICH Q9 and Q10 offer complementary guidelines for pharmaceutical quality systems and quality risk management.

Beginning with the target product profile, the QbD approach proceeds to identify critical quality attributes (CQAs), assess risk, characterise material and process variables, conduct experiments based on Design of Experiments (DoE), create a design space, and develop a control strategy. For controlled-release dosage forms, where dissolving is frequently a crucial quality attribute directly linked to product performance, this strategy is especially pertinent.

2. Research Objectives

2.1 Overall Goal

To create a methodical framework for the creation and improvement of controlled-release oral dosage forms based on Quality by Design.

2.2 Particular objectives

1. To go over the QbD concepts that apply to controlled release oral dose forms.
2. To determine the essential components of the Quality Target Product Profile (QTPP) for formulations with controlled release.
3. To identify the critical quality attributes that affect the performance of the product.
4. Determine the most important critical process parameters and critical material attributes.
5. To evaluate the importance of risk assessment in the creation of formulations with controlled release.
6. To look into how to optimise formulations using Design of Experiments.
7. Drug release was examined in relation to polymer concentration,
8. Polymer characteristics, drug loading, compression force, and coating factors.
9. To assess the drug-release kinetics and dissolution characteristics reported in the literature.
10. To determine the gaps in the present research for the development of QbD-based controlled release formulations.
11. To recommend future lines of inquiry for mechanistic modelling, continuous production, artificial intelligence, and customised medication delivery.

3. Research Enquiries

The project aims to address the following research issues in order to achieve this:

1. How may controlled-release oral dose forms be developed using the concepts of QbD in a methodical

manner?.

2. Which CQAs are most crucial to the effectiveness of controlled-release formulations
3. Which material and process factors have the biggest effects on drug-release behaviour?
4. In comparison to the conventional trial-and-error approach, how may DoE improve formulation optimisation?
5. Including drug-release kinetics and dissolution in QbD-based optimisation.
6. The following are the main drawbacks of current QbD research:
7. How might the development of upcoming QbD-based controlled-release formulations be aided by emerging technologies?

4. Research Hypotheses

4.1 Hypotheses (H₀)

The comprehension and optimisation of controlled-release oral dosage forms are not greatly enhanced by the methodical assessment of formulation and process factors using Quality by Design.

4.2 The other theory (H₁)

The comprehension, resilience, and optimisation of controlled-release oral dosage forms are significantly improved by the methodical assessment of formulation and process variables based on Quality by Design.

4.3 Specific theories

H01: Drug-release behaviour is not significantly impacted by polymer concentration or polymer properties.

H11: Polymer concentration and characteristics have a major impact on drug-release behaviour.

H02: The dissolving profile of controlled release tablets is not significantly impacted by compression force.

H12: The dissolution profile of controlled-release tablets is significantly influenced by compression force.

H03: DoE-based optimisation has no appreciable advantages over traditional formulation development.

H13: Compared to traditional formulation development, DoE-based optimisation provides better knowledge and optimisation.

5. Techniques

5.1 The research design

Pharmaceutical development principles, published formulation studies, regulatory guidelines, and statistical optimisation techniques form the foundation of this work's comprehensive literature-based QbD research methodology.

The methodology consists of

Identification of literature → Study selection → QbD variable identification → Risk categorisation → Data extraction → Comparative analysis → Statistical interpretation → Research gap identification → Future research framework

5.2 Literature Search Technique

To uncover high-quality and pertinent scientific evidence on the application of Quality by Design (QbD) principles in the creation and optimisation of controlled release oral dosage

forms, a systematic search of the literature was planned. Published research on formulation development, critical quality attributes, critical material attributes, critical process parameters, Design of Experiments (DoE), risk assessment, dissolution behaviour, drug-release kinetics, design space, process optimisation, and lifecycle management was the main focus of the search.

Internationally renowned electronic scientific databases, including PubMed, Scopus, Web of Science, ScienceDirect, SpringerLink, Wiley Online Library, Taylor & Francis Online, and Google Scholar, were used to conduct a comprehensive literature search. The regulatory and scientific basis of the QbD framework was also established by taking into account official scientific and regulatory documents published by organisations such as the European Medicines Agency (EMA), the U.S. Food and Drug Administration (USFDA), and the International Council for Harmonisation (ICH).

6. Inclusion and Exclusion Criteria

6.1 Criteria for inclusion and exclusion

Studies could be added if they

- Investigate controlled-release oral dose formulations;
- Apply DoE or QbD principles;
- look at process or formulation variables;
- are published in peer-reviewed journals;
- provide dissolution or drug-release data;
- look into polymer-controlled release methods;
- provide formulation optimisation data; and

6.2 Exclusion Standards -Research may be disregarded if they only discuss immediate-release products;

- lack formulation or process details;
- lack pertinent quality attributes;
- are non-scientific articles;
- offer insufficient comparison data;
- are redundant publications;
- lack pertinent controlled-release performance data.

7. Quality Target Product Profile

The QTPP defines the desired characteristics of the final controlled-release dosage form.

Table 1: Important QTPP parameters include

Parameter	Target
Dosage form	Controlled-release tablet/capsule
Route	Oral
Dose	Therapeutically appropriate
Release pattern	Controlled/sustained
Assay	Within specified limits
Content uniformity	Within acceptable limits
Dissolution	Predetermined release profile
Hardness	Adequate mechanical strength
Friability	Acceptable
Stability	Maintained throughout shelf life
Patient acceptability	Appropriate

For controlled-release products, the dissolution profile should be considered a major component of the QTPP because it determines the temporal availability of the drug.

8. Quality Risk Assessment

Risk assessment should be conducted before extensive experimentation.

Table 2: A risk matrix may be developed using:

Variable	Potential CQA affected	Risk
Polymer concentration	Dissolution	High
Polymer viscosity	Dissolution	High
Drug particle size	Content uniformity/dissolution	Medium–High
Compression force	Porosity/dissolution	High
Lubrication time	Dissolution	Medium
Coating weight gain	Drug release	High
Mixing time	Content uniformity	Medium
Drying temperature	Moisture/stability	Medium

High-risk variables should generally be prioritized for experimental investigation.

9. Data Analysis of Research

Because this publication is intended to be a QbD-oriented review and not a contrived experimental study, the data analysis should be based on published experimental results and stated relationships.

9.1 Descriptive Statistics Analysis

Published studies fall into: type of dosage form Used polymer DoE approach Formulation variables number Period of dissolution testing Release mechanism Optimisation technique Statistical model

Table 3: Example classification

Study Category	Expected Analysis
Matrix tablets	Polymer–release relationship
Osmotic systems	Coating/orifice–release relationship
Bilayer tablets	Layer composition–release relationship
Multiparticulates	Polymercoating–release relationship
3D-printed systems	Geometry/process–release relationship

10. Anticipated Data Interpretation

In the published QbD literature, several general relationships can be identified.

10.1 concentration of polymer

Often the diffusional resistance has been found to increase with increasing polymer content. This can also retard the rate of drug release.

10.2 Viscosity of the polymer

More robust gel barriers are typically created with higher viscosity polymers, but they can also reduce drug diffusion.

10.3 compressive strength

Higher compression force can retard drug release, possibly changing liquid penetration and decreasing tablet porosity.

10.4 thickness of the coat

In membrane-controlled systems, increasing the coating weight growth can reduce the release rate.

10.5 osmotic concentration of active substances

In osmotic systems, the osmotic driving force can influence the rate of drug release and the rate of water inflow.

10.6 The loading of drug

The drug loading can change the diffusion pathways and matrix architecture, which may affect the release kinetics. These correlations should be viewed as general tendencies and not as universal rules, since the magnitude and direction of effects are dependent on the drug, the polymer, the architecture of the formulation and the manufacturing process.

11. Research Gap

Despite significant progress in QbD-based formulation creation, there are still important research gaps.

11.1 Limitations on the integration of process and formulation factors

The production parameters receive relatively less attention than the composition of the formulation, which is the primary focus of most published studies.

Future research ought to assess concurrently

Material characteristics → Formulation variables → Process parameters → Microstructure → Dissolution → Performance

11.2 Inadequate knowledge of mechanisms

Numerous studies use statistical models that do not adequately describe the physical causes underlying variations in drug release.

As a result, statistical and mechanistic modelling must be integrated.

11.3 In vitro-in vivo correlation limitation

In vitro dissolution data provides the foundation for a large portion of QbD research.

To establish significant connections between pharmacokinetic performance and solubility, more investigation is required.

11.4 Limited evaluation of excipient variability

various polymer manufacturers and grades may exhibit various release behaviours. One important area of research that needs to be methodically evaluated is excipient variability within the QbD frameworks.

11.5 Restricted application of AI

Although machine learning and artificial intelligence are being investigated more and more, their use in the development of regular controlled-release formulations is still somewhat limited.

11.6 Patient-Centric Limited QbD

Future QbD development will need to focus more on patient demands, dose flexibility, administration characteristics, and customised therapeutic needs.

12. Study Restrictions and Advantages

There are certain drawbacks to the existing review-based QbD system.

1. The experimental design and analytical methods used in

published studies can differ.

2. The medicine, polymer, excipient, and manufacturing circumstances of the formulations vary significantly.
3. Therefore, it may be difficult to compare studies directly numerically.
4. Studies that report successful optimisation may be more likely to be published.
5. Nevertheless, several studies do not provide complete sets of raw dissolution data.
6. Clinical importance is not usually implied by the statistical significance reported by individual studies.
7. Drug absorption *in vivo* is not usually predicted by *in vitro* dissolution performance.
8. Different QbD research may define criticality differently.
9. The quality and accessibility of training datasets continue to be crucial for AI-based methods.
10. The suggested product-specific QbD framework's experimental validation is contingent upon its deployment.

13. Future Work

The integration of traditional QbD with cutting-edge pharmaceutical development technology should be the focus of future study.

13.1 AI-assisted formulation development

Drug release could be predicted by machine-learning algorithms from:

1. polymer concentration,
2. polymer features,
3. drug solubility,
4. composition of the formulation,
5. compression parameters, and dissolving qualities.

13.2 Mechanisms of modelling

Diffusion, swelling, erosion, and dissolution can all be better understood by combining DoE with mechanistic models.

13.3 Digital twins

Digital twins are capable of simulating industrial processes and forecasting the impact of process modifications prior to their commercial adoption.

13.4 Technologies for Process Analysis

PAT can offer up-to-date information on important process and material characteristics.

13.5 Series production

Continuous manufacturing, when supported by appropriate QbD concepts, can also enhance process control and consistency.

13.6 Controlled Release Dosage Forms Made using 3D Printing

3D printing is no longer in charge: tablet geometry, internal structure, infill density, polymer distribution, medication loading, and release properties.

13.7 Customised medicine

Future QbD systems might make it possible to create

controlled-release formulations that are specific to each patient's therapeutic needs.

14. The significance of the anticipated research

The proposed QbD-based framework's potential importance in the creation of pharmaceutical formulations is examined.

14.1 Scientific significance

It offers a methodical comprehension of how formulation factors, process parameters, and product performance are related.

14.2 Relevance to the sector

This can strengthen manufacturing and lessen the need for trial-and-error experimentation.

14.3 The significance of regulations

This is consistent with contemporary pharmaceutical development principles, which include risk-based control and product and process awareness.

14.4 Clinical significance

This could offer a stable controlled release formulation with easier dosing and more consistent medication exposure.

14.5 Economic significance

Systematic formulation optimisation could reduce production variability, needless experiments, formulation failures, and scale-up issues.

15. Conclusion

A scientifically sound framework for the creation and improvement of controlled-release oral dosage forms is provided by the Quality by Design method. Critical Quality Attributes, Critical Material Attributes, and Critical Process Parameters are identified when the Quality Target Product Profile is defined.

Design of Experiments offers a statistically effective method of identifying primary effects and interactions, while risk assessment aids in prioritising variables for study. By carrying out methodical research on dissolution behaviour, polymer concentration, polymer properties, compression force, coating variables, and other formulation and process variables, correlations between formulation composition and product performance can be established.

Formulation robustness and manufacturing consistency can be improved by developing a design space and control plan that is supported by science. Significantly, QbD transforms pharmaceutical development from a trial-and-error method to a knowledge-based and risk-based methodology.

Poor formulation and manufacturing variable integration, a lack of mechanistic understanding, poor *in vitro-in vivo* correlation, excipient variability, and comparatively poor use of artificial intelligence and patient-centric development are the main research gaps.

Mechanistic modelling, AI, machine learning, Process Analytical Technology, continuous production, digital twins, and 3D printing should all be integrated with QbD in future research. Faster, more reliable, adaptable, and customised controlled-release medication administration systems could result from such integration.

Therefore, QbD is a comprehensive, science-based method

to incorporating quality, performance, and resilience into controlled-release oral dosage forms from the outset of pharmaceutical development, rather than just a regulatory strategy.

16. References

1. Atre P, Rizvi SAA. Advances in oral solid drug delivery systems: quality by design approach in development of controlled release tablets. *BioChem.* 2025;5(2):9.
2. Suksaeree J, Monton C, Maneewattanapinyo P. Quality by design integration of design of experiments for tablet formulation optimization and process validation. *AAPS Pharm SciTech.* 2026;27(2):94.
3. Quality by design approach to understand the physicochemical phenomena involved in controlled release of captopril sustained-release matrix tablets. *International Journal of Pharmaceutics.* 2014.
4. Quality by design-based numerical and graphical optimization technique for the development of osmotic pump controlled-release metoclopramide HCl tablets. *Drug Design, Development and Therapy.* 2020.
5. Design and optimization of bilayered tablet using the quality-by-design approach. *Journal of Drug Delivery.* 2014.
6. Pharmaceutical product development: a quality by design approach. *Journal of Pharmacy and Bioallied Sciences.* 2016.
7. QbD guided development of 3D-printed tablets with customizable API doses. 2022.
8. European Medicines Agency. ICH Q8, Q9 and Q10 Questions and Answers (R5). 2025.

Creative Commons (CC) License

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY 4.0) license. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.